Trade Desk (NASDAQ:TTD) Stock, Quote.Headers.trade-ideas

Trade Desk

The Trade Desk provides a self-service platform that helps advertisers and ad agencies programmatically find and purchase digital ad inventory (display, video, audio, and social) on different devices like computers, smartphones, and connected TVs. It utilizes data to optimize the performance of ad impressions purchased. The firm's platform is referred to as a demand-side platform in the digital ad industry. The firm generates its revenue from fees based on a percentage of what its clients spend on advertising.

Roku's Rise with Streaming

Analyst Color

Technicals

Analyst Ratings

Tech

Trading Ideas

ROKU

SHOP

Roku Inc. (NASDAQ:ROKU) is focused on platform revenue growth, launching Ads Manager and partnerships for shoppable ads. Needham sees a $100 price target.

Roku: The &#39;Arms Dealer&#39; Of Streaming Gears Up For Monetization Surge, Says Analyst

fed ai5

Macro Economic Events

News

Sector ETFs

Broad U.S. Equity ETFs

Small Cap

Econ #s

Economics

Federal Reserve

Markets

Movers

ETFs

$BTC

$ETH

SPDR Dow Jones Industrial Average ETF Trust

iShares Trust Barclays 20+ Year Treasury Bond Fund

Editor’s note: This story has been updated with additional information. 

S&amp;P 500, Gold Strike All-Time Highs, Small Caps Rally After Fed Slashes Interest Rates For First Time In 4 Years (UPDATED)

Pre-market: 5 titoli da monitorare oggi, 6 settembre 2024

Long Ideas

Media

AVGO

On CNBC&#39;s &#34;Halftime Report Final Trades,&#34; Kari Firestone of Aureus Asset Management said Broadcom &#34;is a good buy here.&#34;

Broadcom, Trade Desk, AppLovin And A Big Bank On CNBC&#39;s &#39;Final Trades&#39;

The Trade Desk, Inc. - Class A Common Stock

The Trade Desk Inc

TDK Corp

Biotech

General

ALGS

Aligos Therapeutics Announces Results From Phase 2a HERALD  Study Showing ALG-055009 Dose Groups Met Primary Endpoint With Statistically Significant Reductions In Liver Fat At Week 12

ARQT

Arcutis Announces Publication Of Phase 3 Results For ZORYVE (Roflumilast) Cream 0.15% In JAMA Dermatology, Demonstrating Significant Efficacy And Safety In Treating Mild To Moderate Atopic Dermatitis In Adults And Children

Piper Sandler analyst Michael Lavery maintains General Mills (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIS#NYSE">GIS</a>) with a Overweight and raises the price target from $74 to $84.

Price Target

Piper Sandler Maintains Overweight on General Mills, Raises Price Target to $84

GLMD: 60% &#x7C; <a href="https://www.benzinga.com//node/40935862">Galmed Pharmaceuticals Plans To Broaden Its Drug Development Activities, Consisting Of Two Additional Programs Over The Next Two Years</a>
&nbsp;
EWTX: 42% &#x7C; <a href="https://www.benzinga.com//node/40935611">Edgewise Therapeutics Announced Top-line Data Of EDG-7500 From The Phase 1 Trial In Healthy Subjects And The Single-dose Arm Of Phase 2 CIRRUS-HCMtrial In Patients With Obstructive Obstructive Hypertrophic Cardiomyopathy</a>
&nbsp;
XCUR: 271% &#x7C; <a href="https://www.benzinga.com//node/40927738">Exicure shares are trading higher after the company announced it received an extension from the Nasdaq Hearings Panel.</a>

EWTX

GLMD

XCUR

Market-Moving News for September 19th

TD Cowen analyst Andrew Charles reiterates Darden Restaurants (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) with a Hold and maintains $150 price target.

Reiteration

TD Cowen Reiterates Hold on Darden Restaurants, Maintains $150 Price Target

Apple, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) shares came under pressure <a href="https://www.benzinga.com/tech/24/09/40930388/apple-iphone-16-pre-orders-show-possible-low-demand-one-sign-could-point-to-company-breaking-this-em">following commentary about demand immediately after pre-orders began </a>but a bullish analyst explained on Wednesday why the early trends should not be a cause for worry.
The Apple Analyst: Morgan Stanley analyst Erik Woodring has an Overweight rating and a $273 price target for Apple.
The Apple Thesis: iPhone 16 lead times have doubled from last Friday and have been longer internationally than in the U.S., but it is still tracking lower year-over-year, said Woodring in a note. As of Sept. 17, four days after preorders started:
<ul>
<li>The U.S. lead time is 14.4 days, up 100% from last Friday;</li>
<li>But lower than the 21.6-day average for all iPhone 15 models during the same period last year;</li>
<li>And 18-day average for all iPhone 14 models four days after preorders started in 2022.</li>
</ul>
Morgan Stanley&#8217;s tracking model going back to 2017 showed there is a directional, positive relationship between average lead times in the first two weeks after preorders began and the strength of iPhone shipments over the 12 months, Woodring said. &#8220;The longer the average lead time in the first two weeks after pre-orders begin, generally, the stronger the next 12-month shipments are for that specific iPhone model,&#8221; he said. 
That said, no strong correlation exists when comparing new iPhone model lead times in the first two weeks until the December quarter and total shipments over the next 12 months, the analyst said. &#8220;This is because lead times are influenced by both supply and demand, making iPhone lead times as a proxy this early in the cycle not yet truly informative,&#8221; he said.
See Also: <a href="https://www.benzinga.com/money/best-tech-stocks">Best AI Stocks Right Now</a>
According to the analyst, the shorter lead times this time around could be due to:
<ul>
<li>Apple directing the supply chain to build 5% more iPhone 16s in the second half of the calendar year 2024 than iPhone 15s during the comparable period in 2023;</li>
<li>The key reason for upgrading to the iPhone 16, <a href="https://www.benzinga.com/news/24/09/40780100/apple-intelligence-ready-iphone-16-with-faster-processor-dedicated-camera-button-announced-check-pri">Apple Intelligence features,</a> may not be available in the U.S. until October. In the U.K. it would be available only later this year, and the Chinese and Japanese customers get those only next year. This could be delaying upgrades, Woodring said.</li>
</ul>
The Apple Stock: Looking at stock implications, Woodring said at $216, Apple traded at a relatively full 29 times Morgan Stanley&#8217;s 2025 earnings per share estimate of $7.50. Any near-term outperformance from here would have to come from a growth acceleration/positive earnings revisions, he said. 
That said, the analyst noted that the December quarter iPhone builds have been revised lower by 3-6 million units over the last decade. Every one million iPhone build reduction equates to 4-cent earnings per downside, with Apple&#8217;s price/earnings multiple contracting by 1.5 times, on average, in the three months after an iPhone launch, he said.
The analyst sees downside support for the stock around $197, which translates to $7.30 per share in earnings per share and 27 times multiple. 
But most bulls see the fiscal year 2026 and the iPhone 17 as the bigger cycle and any estimate cuts or near-term stock underperformance will likely get bought, leading to just a short window of underperformance before investors turn their attention to the iPhone 17 and FY26 earnings power, he said.
In premarket trading, Apple shares climbed 1.62% at $224.27, according to <a href="https://benzinga.grsm.io/register174">Benzinga Pro data.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40914325/apple-stock-reaction-after-iphone-launch-sparks-portfolio-managers-reflection-i-may">Apple Stock Reaction After iPhone Launch Sparks Portfolio Manager&#8217;s Reflection: &#8216;I May Be Wrong In The Short Term But&#8230;Will Be Back In The Long Run&#8217;</a></li>
</ul>
Image via Unsplash

Equities

AAPL

Apple Analyst Shrugs Off Lukewarm Early iPhone 16 Demand Trends: Here's Why Soft Preorder Data Hasn't Dented Morgan Stanley's Bullish Thesis

Enables Qualifying Customers to Use HSA (Health Savings Account) or FSA (Flex Savings Account) Funds to Purchase BODi Nutritional Supplements and Fitness Offerings
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fthebeachbodycompany.com%2F&amp;esheet=54123782&amp;newsitemid=20240919616045&amp;lan=en-US&amp;anchor=The+Beachbody+Company%2C+Inc.&amp;index=1&amp;md5=a68ffec7f8eedd2d6d2930e2cd127850">The Beachbody Company, Inc.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BODI#NYSE">BODI</a>) ("BODi"), a leading fitness and nutrition company, announced today a strategic partnership with <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.truemed.com%2F&amp;esheet=54123782&amp;newsitemid=20240919616045&amp;lan=en-US&amp;anchor=Truemed&amp;index=2&amp;md5=acec2721783fbebd5219ef6637be2923">Truemed</a>, a leading healthcare payment provider that helps qualified customers spend their HSA/FSA funds on supplements, exercise and other lifestyle interventions that can help treat or prevent chronic disease. The partnership enables qualifying BODi customers to use their pre-tax HSA or FSA money to pay for supplement purchases from BODi's best-in-class product portfolio, including its Shakeology superfood nutrition shakes. By using pre-tax income for purchases, BODi customers can access their supplements at a significant discount.
To access the partnership, current and new BODi customers can take an online medical assessment with Truemed to determine if they qualify for a Letter of Medical Necessity (LMN). If approved, the LMN is valid on all supplement purchases for a year and allows customers to save up to 40% on BODi supplements, including both one-time and monthly subscription purchases.

The Beachbody Company, Inc. Class A Common Stock

BODI

BODi And Truemed Partner To Provide Pre-Tax Reimbursement For BODi Health And Fitness Supplements

AEMD

Aethlon Receives Ethics Committee Approval For Hemopurifier Cancer Trial In India, Targeting Patients With Solid Tumors Unresponsive To Anti-PD-1 Therapy

Piper Sandler analyst Patrick Moley maintains Robinhood Markets (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) with a Overweight and raises the price target from $23 to $27.

HOOD

Piper Sandler Maintains Overweight on Robinhood Markets, Raises Price Target to $27

<a href="https://www.globenewswire.com/Tracker?data=IOZSQF7l2NlW9dojiDWx9HMQptoABpF2Il4ywCXA5XTPitneEGZNU0z2MWDTAUvxuelopl_woOJhmiPtw5Rn-w==">CorMedix Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today announced that it has entered into a new commercial supply contract with a top-tier mid-sized dialysis operator for the supply of DefenCath&#xAE; (taurolidine and heparin) to dialysis clinics in the US. This new agreement will provide access to DefenCath for adult patients with kidney failure receiving hemodialysis through a central venous catheter at more than 250 outpatient dialysis clinics located across the United States. &nbsp;
CorMedix received NDA approval of DefenCath under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD) on November 15, 2023, and began commercialization of the product in the inpatient setting on April 15, 2024. Outpatient reimbursement of DefenCath from the Center for Medicare &amp; Medicaid Services (CMS) took effect on July 1st, and CorMedix subsequently commenced the shipment of orders to outpatient dialysis facilities in July. CorMedix anticipates shipments for DefenCath under this agreement to begin in the beginning of the fourth quarter.

CRMD

CorMedix Inc. Announces New Commercial Agreement To Provide Access To DefenCath For Adult Patients With Kidney Failure Receiving Hemodialysis Through A Central Venous Catheter At More Than 250 Outpatient Dialysis Clinics Located Across The United States

AIM ImmunoTech Announces Prelim. Data From Phase 1b/2 Study Of Ampligen And Imfinzi; Says 'Preliminary finding of stable disease in two out of three patients at 6 months in the first subject cohort'

AMZN

NTAP

NetApp Signs Strategic Collaboration Agreement With AWS To Enhance Cloud-Based Data Services, Accelerate Generative AI Efforts, And Drive CloudOps Value

Cracker Barrel Old (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBRL#NASDAQ">CBRL</a>) reported quarterly earnings of $0.98 per share which missed the analyst consensus estimate of $1.10 by 10.91 percent. This is a 45.25 percent decrease over earnings of $1.79 per share from the same period last year. The company reported quarterly sales of $894.39 million which missed the analyst consensus estimate of $897.22 million by 0.32 percent. This is a 6.89 percent increase over sales of $836.73 million the same period last year.

Earnings

Earnings Misses

CBRL

Cracker Barrel Old Q4 Adj $0.98 Misses $1.10 Estimate, Sales $894.39M Miss $897.22M Estimate

EVAX

Evaxion Announces An Update Of Its EDEN AI Prediction Model, Featuring A Novel Toxin Antigen Predictor

<a href="https://www.globenewswire.com/Tracker?data=5jgK2-b8x7-bCcNdJPov_gm8LWrdhiPzE6BWpC5q-uC-832qloMe-mb-28Azf_hgW4HcdAKMAutKNMZzjx5f_Q==">LifeMD, Inc.</a><a href="https://www.globenewswire.com/Tracker?data=51jmIb3lT-TliDCB6Db_FvWaAdiE7waFYPNh9AQXPaK9kK2GmIJYglyXC2C4YkfU">&#xAE;</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFMD#NASDAQ">LFMD</a>), a leading provider of virtual primary care services, today announced significant enhancements to its weight management program, underscoring the company's commitment to expanding patient access and improving the quality and comprehensiveness of care available on its virtual care platform. The investments include a new and improved platform and partnership for in-home lab collection, technology enhancements for prior authorization and pharmacy benefits infrastructure, and the launch of personalized prescription treatment options. These advancements further establish LifeMD as a leader in the rapidly growing market for virtual healthcare.
As part of its commitment to increasing access to branded prescription GLP-1 medications, LifeMD has developed and is launching a real-time electronic benefit verification program that allows patients to check pharmacy benefits verification before enrolling in a LifeMD virtual care program. Additionally, LifeMD has partnered with an AI-powered platform that optimizes prior authorization submissions and appeals to improve approval rates for patients. These enhancements are designed to minimize delays in care, reduce barriers to accessing brand-name medications, and ensure that a broader range of patients can benefit from LifeMD's offerings.

LFMD

LifeMD Announces Enhancements To Its Weight Management Program, Expanding Patient Access To Branded GLP-1 Therapies And Introducing New Treatment Options

HUMA

Humacyte Announces U.S. Patent Allowance For BioVascular Pancreas (BVP), Supporting Potential Treatment For Type 1 Diabetes

New Nano-Grid System '<a href="https://www.globenewswire.com/Tracker?data=WkyeP-xg0-zKIG1giac2fw17vDet6ffDyr7K78Hfhf2qReoNiyhFk_aavxtK-Y3Uo0ux0oMZeapoRCs3puOvKNFODEtf8JisTS4Bd1BN7fs=">SOLIS' and 'COR'</a> Stores 4,000Wh or more of Clean Energy Daily, Offering Modular, Portable Power Solutions for Vehicles, Jobsites, First Responders, Military, and Outdoor Enthusiasts. &nbsp;
West Seneca, New York, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Worksport Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKSP#NASDAQ">WKSP</a>) ("Worksport" or the "Company"), a U.S.-based manufacturer and innovator of hybrid and clean energy solutions for the light truck, overlanding, and global consumer goods sectors, is excited to announce a major update on its innovative, much anticipated, nano-grid system, known as "SOLIS &amp; COR." This system includes the SOLIS solar tonneau cover and the COR portable energy system. The plan to bring this system to market is strategically arranged in three phases: Alpha release, Beta release, and full-scale market launch. The Alpha release phase has been initiated, with approximately 100 systems set for rigorous testing and public exposure during this initial market release.

WKSP

Worksport Initiates Alpha Launch Of Solis Solar Array And COR Mobile Battery Power Generator; New Nano-Grid System 'SOLIS' And 'COR' Stores 4,000Wh Or More Of Clean Energy Daily, Offering Modular, Portable Power Solutions For Vehicles, Jobsites, First Responders, Military, And Outdoor Enthusiasts

PGNY

Progyny Late Wednesday Said A Client Elected To Exercise A 90-Day Option To Terminate Its Services Agreement With The Company, Effective Jan. 1

Throughout the last three months, 4 analysts have evaluated Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>), offering a diverse set of opinions from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $43.75, along with a high estimate of $53.00 and a low estimate of $37.00. A decline of 7.41% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2024/1726747277_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A clear picture of Staar Surgical's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thomas Stephan</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$44.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Jon Young</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$41.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$53.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$37.00</td>
<td>$50.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Staar Surgical. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Staar Surgical compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
For valuable insights into Staar Surgical's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/STAA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Staar Surgical analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Staar Surgical</h2>
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of sales are generated from the ophthalmic surgical product segment.
<h3>A Deep Dive into Staar Surgical's Financials</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Staar Surgical displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 7.26%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Staar Surgical's net margin excels beyond industry benchmarks, reaching 7.45%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Staar Surgical's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.84% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.47%, the company showcases effective utilization of assets.
Debt Management: Staar Surgical's debt-to-equity ratio is below the industry average at 0.09, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

STAA

Analyst Scoreboard: 4 Ratings For Staar Surgical

WIIM

Carnival shares are trading higher after Mizuho maintained an Outperform rating on the stock and raised its price target from $22 to $25.

BofA starts The Trade Desk at Buy on strong moat amid ad shifts

Meta Platforms, MercadoLibre, and DoorDash are top Internet picks at Cantor Fitzgerald

What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of Sept. 2-6, 2024.

Wall Street's Top 10 Stock Calls This Week - Saturday, Sept. 7

Rowan Street Q2 2024 Letter

Analysts have been eager to weigh in on the Technology sector with new ratings on Trade Desk (TTD – Research Report) and Array Technologies (ARRY –...

Analysts Offer Insights on Technology Companies: Trade Desk (TTD) and Array Technologies (ARRY)

Just a few days ago, we heard about Roku ($ROKU) bringing back the NFL Zone, an experience that will certainly endear it to at least some sports fa...

Roku (NASDAQ:ROKU) Ramps Up its Sports Plans

Sonos and Trade Desk are developing a TV streaming device - report

The Trade Desk: This Journey Has Been Far From A Smooth Ride-Much

The Trade Desk: This Journey Has Been Far From A Smooth Ride

Google: Overstated Break-Up Fears

ABNB

ARRY

BKNG

CART

CNSWF

DASH

EBAY

ETSY

EVTC

EXPE

GDDY

GOOG

GOOGL

LYFT

MELI

MSFT

NFLX

ORCL

PINS

SNAP

SONO

SPOT

TOITF

TRNO

UBER

XPEV

Press Releases

The Trade Desk Reports Fourth Quarter and Fiscal Year 2023 Financial Results

The Trade Desk Announces Date of First Quarter 2024 Financial Results and Conference Call

Roku and The Trade Desk Announce New Data-Driven TV Streaming Partnership

VerticalScope Partners with The Trade Desk to Integrate OpenPass and OpenPath

The Trade Desk Reports First Quarter 2024 Financial Results

The Trade Desk Unveils the Sellers and Publishers Report – a Biannual Review of Open Internet Trends

Entertainment

FOX AND THE TRADE DESK ANNOUNCE EXTENSIVE ADVERTISING INTEGRATIONS ACROSS FOX PORTFOLIO

The Trade Desk Announces Date of Second Quarter 2024 Financial Results and Conference Call

The Trade Desk Reports Second Quarter 2024 Financial Results

Admiral Secures $19M in New Funding, Led by Harbert Growth Partners, Reaching $28M Total Raised to Save the Free Internet, One Publisher at a Time

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Trade Desk

Trade Desk (TTD) Forecast

Trade Desk (NASDAQ:TTD) Stock, Quote.Headers.trade-ideas